Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Inclusion Criteria: * Patients must have histologically or cytologically confirmed solid organ malignancy * Patients enrolled in the expansion cohort must have histologically or cytologically confirmed squamous non-small cell lung cancer (NSCLC), breast or pancreaticobiliary tract cancer * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm (≥ 2 cm) with conventional techniques or as ≥ 10 mm (≥ 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam * Leukocytes ≥ 3,000/mL * Absolute neutrophil count ≥ 1,500/mL * Platelets ≥ 100,000/mL * Hemoglobin ≥ 10 g/dL * Total bilirubin ≤ 1.5 × institutional upper limit of normal (except for patients with Gilbert disease) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 2.5 × institutional upper limit of normal (up to 5 X upper limit of normal \[ULN\] for patients with liver metastasis) * Creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal * Women of child-bearing potential and men must agree to use adequate contraception (ho…